Comparison
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 vs 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
Clinical comparison between 46 XX Disorder OF Sex Development Induced BY Fetoplacental Androgens Excess and 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency for differential diagnosis and treatment planning.
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
A condition where the placenta and fetus together produce excess androgens, affecting an XX embryo's development. It is present at birth. Multidisciplinary care helps manage physical and hormonal aspects.
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
A rare condition affecting how certain hormones are processed in the body, which can influence sexual development. Treatment may involve hormone therapy and specialist care.
6 comparison axes
Onset
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
Variable
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
0-16
Onset patterns differ
Severity
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
severe
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
moderate
Different severity levels
Chronic
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
Chronic
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
Chronic
Differing course
Communicable
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
No
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
No
Different transmission
Body System
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
reproductive
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
endocrine
Same/different system
Category
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
endocrine
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
endocrine
Different category
Bottom line
46-xx-disorder-of-sex-development-induced-by-fetoplacental-androgens-excess-C5679876 and 3-oxo-5-alpha-steroid-delta-4-dehydrogenase-deficiency-C0268297 differ in severity
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 | 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 | Discriminating power |
|---|---|---|---|
| Genital appearance at birth | May show androgen-related atypical development in a 46,XX infant, present from birth. | May affect genital development, often recognized from birth through adolescence. | Moderate |
| Karyotype context | Defined in an XX embryo exposed to excess fetoplacental androgens. | Not defined by XX karyotype; enzyme pathway is the core issue. | High |
| Hormone-processing pattern | Excess androgen production involving fetus and placenta is the stated mechanism. | Impaired conversion in the 5-alpha-steroid pathway may reduce DHT relative to testosterone. | High |
When to favor each condition
Choose 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 when
Atypical genitalia in a confirmed 46,XX newborn
The left concept specifically concerns XX development with fetoplacental androgen excess.
Moderate
Prenatal or placental androgen source is suspected
Source descriptions implicate combined fetal and placental androgen production.
Moderate
Severe congenital reproductive phenotype needing multidisciplinary care
Supplied severity is severe and care includes physical and hormonal aspects.
Low
Choose 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 when
Suspected disorder of androgen activation rather than excess production
The right concept concerns deficient steroid delta-4-dehydrogenase activity.
Moderate
Findings emerge or are clarified between birth and age 16
Supplied onset range is 0-16 years, unlike a strictly birth-defined left concept.
Moderate
Endocrine pathway evaluation is the main question
Body system is listed as endocrine and treatment may include hormone therapy.
Low
How key tests differ
| Test | 46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876 | 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 | Interpretation |
|---|---|---|---|
| Karyotype | 46,XX is part of the concept definition. | Karyotype is not specified by the supplied data. | XX status supports considering the left concept but does not prove the mechanism. |
| Androgen pathway studies | Pattern should be interpreted for excess androgen exposure; exact cutoffs are not established here. | May show impaired testosterone-to-DHT processing; ratios require specialist interpretation. | Abnormal results are not diagnoses and must be confirmed clinically. |
| Genetic or enzyme evaluation | No specific gene or cutoff is supplied. | Testing may target the relevant dehydrogenase pathway when clinically indicated. | Choice and meaning of tests belong to an experienced clinician. |
Prognosis comparison
46 Xx Disorder Of Sex Development Induced By Fetoplacental Androgens Excess C5679876
- Outcome
- Chronic congenital condition; specific survival or fertility outcomes are not established here.
- Factors
- Severity is listed as severe; individual anatomy, hormones, and care access matter.
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
- Outcome
- Chronic endocrine condition of moderate listed severity; outcomes vary.
- Factors
- Timing of recognition, hormone pattern, and response to specialist care may influence course.
Time frame: From birth, with the right concept potentially recognized through age 16; lifelong follow-up may be needed.
No prevalence, mortality, or treatment-dose data should be inferred from this comparison.
Complications comparison
| Complication | Presentation |
|---|---|
| Atypical genital development | Can be present at birth and may be severe. Can occur and may be recognized across childhood or puberty. Degree and management needs vary; do not infer a fixed outcome. |
| Hormonal imbalance | Linked to excess fetoplacental androgens. Linked to impaired processing of certain androgens. Both may need endocrine follow-up; doses are not specified. |
| Psychosocial impact | Congenital findings may affect family decisions and identity-sensitive care. Pubertal or childhood changes may raise similar support needs. Impact is individual and not quantified in the source data. |
Patient education highlights
- HighSpecialist confirmation
These labels require genetics, endocrinology, and often urology or gynecology review before decisions.
- HighTests versus diagnosis
An abnormal hormone result does not by itself establish either condition.
- MediumLong-term care
Both are described as chronic and may involve hormone therapy and coordinated support.